Around 1 in 5 patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) experienced target lesion failure (TLF) within 10 years, ...

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be ...

Please provide your email address to receive an email when new articles are posted on . A bioadaptor implant adaptable to vessel physiology conferred better outcomes from 6 months to 1 year vs. a DES.

The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year ...

SAN FRANCISCO – OCTOBER 26, 2025 – New study results from a large international all-comer population of percutaneous coronary intervention (PCI) candidates found that utilizing a strategy of sirolimus ...

The Bioadaptor coronary implant (Elixir Medical) continues to outperform contemporary drug-eluting stent technology over ...

A paclitaxel-coated balloon, Agent DCB (Boston Scientific), was superior to an uncoated balloon for treating coronary in-stent restenosis in patients undergoing percutaneous coronary intervention (PCI ...

At EuroPCR 2026, experts highlighted major advances in the treatment of previously untreatable calcified coronary lesions.

Please provide your email address to receive an email when new articles are posted on . Immediate PCI of nonculprit lesions in STEMI did not confer better outcomes vs. a deferred strategy. Risks for ...

Operators safely shaved a few minutes off heart attack reperfusion times by taking patients straight to culprit lesion percutaneous coronary intervention (PCI) when they arrived at the catheterization ...